Lotus Eye Hospital And Institute Ltd (LOTUSEYE) AI Stock Analysis

• Market Cap: ₹2.42B
• Dividend Yield: N/A
• Average Volume (3M): 3.63K
• Price to Earnings (P/E): 371.3
• Beta (1Y): 1.05
• Revenue Growth: 3.41%
• EPS Growth: -69.33%
• Country: IN
• Employees: 336
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.26
• Shares Outstanding: 20,796,330
• 10 Day Avg. Volume: 3,592
• 30 Day Avg. Volume: 3,633
• PEG Ratio: -2.60
• Price to Book (P/B): 2.43
• Price to Sales (P/S): 2.94
• P/FCF Ratio: -68.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: ₹121.00 ▲(2.46% Upside)

Lotus Eye Hospital And Institute Ltd's overall score reflects strong financial growth and a solid balance sheet, but is weighed down by declining profitability and high valuation concerns. Technical indicators show mixed signals, adding to the cautious outlook.

Lotus Eye Hospital And Institute Ltd Business Overview & Revenue Model

Company Description

Lotus Eye Hospital and Institute Limited, an eye hospital, provides eye care services in India. It offers services in the areas of refractive surgery, retina and uvea, cornea, glaucoma, paediatric and squint, computer vision syndrome, orbit and oculoplasty, neuro ophthalmology, and binocular vision. The company also provides cataract and intraocular lenses, as well as operates an eye bank. In addition, it offers ophthalmic fellowship training courses in cornea, glaucoma, retina, and anterior segments, as well as DNB teaching and training services. The company was formerly known as Lotus Eye Care Hospital Limited and changed its name to Lotus Eye Hospital and Institute Limited in April 2013. Lotus Eye Hospital and Institute Limited was incorporated in 1997 and is based in Coimbatore, India.

How the Company Makes Money

LOTUSEYE generates revenue primarily through its medical services and surgeries, which include consultations, diagnostic tests, and various surgical procedures related to eye care. The hospital charges fees for outpatient consultations, inpatient treatments, and surgical interventions, which form the bulk of its income. Additionally, LOTUSEYE may earn revenue from the sale of ophthalmic products, such as eyeglasses, contact lenses, and medications. The company may also benefit from partnerships with insurance providers, which can lead to increased patient volume through covered services. Further revenue can come from specialized eye care programs or community outreach initiatives that promote eye health awareness and preventative care.

Lotus Eye Hospital And Institute Ltd Financial Statement Overview

Summary

Lotus Eye Hospital And Institute Ltd demonstrates strong revenue growth and a solid financial foundation. However, decreasing profit margins and negative free cash flow in recent years highlight the need for careful cost management and strategic capital allocation to maintain financial health. The balance sheet's low leverage provides a cushion against financial risks, but the company should focus on improving profitability and cash flow generation.

Income Statement

Lotus Eye Hospital And Institute Ltd has shown steady revenue growth, moving from ₹316.67M in 2021 to ₹495.62M in 2025. The Gross Profit Margin has decreased over the years, from 50.56% in 2021 to 20.26% in 2025, indicating increased cost pressures. The Net Profit Margin has also declined, reflecting challenges in maintaining profitability despite revenue growth.

Balance Sheet

The company maintains a strong equity base with Stockholders' Equity at ₹600.00M in 2025. The Debt-to-Equity ratio is low, suggesting prudent leverage management. However, the Equity Ratio has slightly decreased, indicating a marginal increase in liabilities over time. Overall, the balance sheet remains robust, providing a stable financial foundation.

Cash Flow

Operating Cash Flow has seen fluctuations but remained positive, providing a reliable cash flow source. However, Free Cash Flow has turned negative in recent years, driven by increased capital expenditures, indicating potential liquidity concerns if not balanced with future revenue growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	501.89M	495.63M	482.10M	470.44M	389.10M	323.59M
Gross Profit	223.00M	100.41M	135.66M	121.38M	192.53M	85.70M
EBITDA	44.41M	47.44M	79.42M	88.37M	68.09M	44.59M
Net Income	6.61M	7.39M	29.14M	40.77M	29.84M	15.68M
Balance Sheet
Total Assets	0.00	695.74M	666.27M	631.88M	615.97M	592.29M
Cash, Cash Equivalents and Short-Term Investments	41.51M	39.78M	69.30M	83.31M	87.93M	98.92M
Total Debt	0.00	34.30M	11.10M	6.70M	12.38M	3.99M
Total Liabilities	-600.00M	95.73M	72.17M	56.09M	69.88M	65.32M
Stockholders Equity	600.00M	600.00M	594.09M	575.79M	546.09M	526.97M
Cash Flow
Free Cash Flow	0.00	-21.25M	403.00K	12.90M	-2.73M	22.55M
Operating Cash Flow	0.00	27.02M	56.83M	43.87M	44.12M	27.30M
Investing Cash Flow	0.00	-43.50M	-46.33M	-21.94M	-39.35M	4.86M
Financing Cash Flow	0.00	-12.42M	-34.02M	-17.05M	-15.75M	-3.19M

Lotus Eye Hospital And Institute Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 118.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LOTUSEYE, the sentiment is Positive. The current price of 118.1 is below the 20-day moving average (MA) of 120.47, above the 50-day MA of 113.93, and above the 200-day MA of 80.34, indicating a neutral trend. The MACD of 0.89 indicates Positive momentum. The RSI at 49.15 is Neutral, neither overbought nor oversold. The STOCH value of 22.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LOTUSEYE.

Lotus Eye Hospital And Institute Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HCG	67 Neutral	₹103.33B	275.51	―	―	16.85%	-29.57%
VIJAYA	67 Neutral	₹103.08B	67.91	―	0.20%	22.34%	20.71%
KRSNAA	63 Neutral	₹25.65B	31.39	―	0.34%	13.78%	32.21%
LOTUSEYE	58 Neutral	₹2.42B	371.26	―	―	3.41%	-69.33%
SHALBY	58 Neutral	₹26.62B	1,145.00	―	0.48%	13.03%	-100.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%